Consensus Guidance for Beta-Lactam Antibiotic Dose Individualization in Acutely Ill Patients: Endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiology and Infectious Diseases PK/PD of Anti-Infectives Study Group, Infectious Diseases Society of America, International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Society of Critical Care Medicine, and the Society of Infectious Diseases Pharmacists.

Pharmacotherapy·August 1, 2026·PMID 42487243

Why it matters

Acutely ill patients exhibit highly variable beta-lactam pharmacokinetics, and standard dosing often leads to subtherapeutic or toxic concentrations. This guidance offers a practical framework for clinicians to optimize beta-lactam therapy through TDM, potentially improving outcomes in severe infections.